RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > FDA Bans Pharma, Nutraceutical and Cosmetic Imports from Canadian Company

FDA Bans Pharma, Nutraceutical and Cosmetic Imports from Canadian Company

Posted 29 September 2015 | By Zachary Brennan 

FDA Bans Pharma, Nutraceutical and Cosmetic Imports from Canadian Company

The US Food and Drug Administration (FDA) has added Canada's Cosmetic Manufacturers Inc. (CMI) to a list of companies that have been banned from shipping products to the US.

CMI manufactures cosmeceuticals, nutraceuticals and pharmaceuticals, including a digestive enzyme therapy, according to its website. The company says it has a Drug Establishment License and owns the rights to many Drug Identification Number products under the CMI name.

The updated FDA import alert list did not go into detail about the violations that caused CMI to be added to it, though it did cite current good manufacturing practice (cGMP) issues.

Warning Letter

In an FDA warning letter to the company from 2013, agency inspectors at CMI's Concord, Ontario manufacturing site said they identified significant cGMP violations. Among those, the company failed to withhold from use each lot of components, drug product containers, and closures until the lot had been sampled, tested, or examined and released for use by the quality control unit.

CMI also failed to establish and follow written procedures for the preparation of master production and control records, which can assure batch uniformity. The possibility of cross-contamination was another issue FDA cited as a reason for the letter.

In addition, CMI failed to register with the FDA in 2011 and 2012 as a firm that manufactures and imports drugs to the US.

The company could not be reached for comment by press time as the phone number listed on its web site is no longer in service.

Import Alert List

Regulatory Focus newsletters

All the biggest regulatory news and happenings.


Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.